Cytotoxic drugs contract manufacturing market | Coherent Market Insights

1. Coherent Marketing Insights https://www.coherentmarketinsights.com/ Market Research & Business Consulting Services Covid-19 Impact Tracker

2. CYTOTOXIC DRUGS CONTRACT MANUFACTURING MARKET ANALYSIS Cytotoxic Drugs Contract Manufacturing Market, by Production Scale (Industrial Scale, Pilot Scale, and Laboratory Scale), by Form (Liquid, and Solid), by Product Type (Oral and Intravenous), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

3. Global Cytotoxic Drugs Contract Manufacturing Market,by Production Scale (Industrial Scale, Pilot Scale, and Laboratory Scale), by Form (Liquid, and Solid), by Product Type (Oral and Intravenous), and by Region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 6,285.2 million in 2018, and is expected to exhibit a CAGR of 9.1% over the forecast period (2019-2027), as highlighted in a new report published by . Governments in emerging economies such as India are focusing on initiatives to increase domestic production. For instance, in August 2017, according to the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers of government of India proposed 'peak customs duty' and suggested setting up of bulk drug parks to increase domestic production.

4. Furthermore, rapid growth in the pharmaceutical industry in the Asia Pacific region is expected to propel growth of cytotoxic drug contract manufacturing market in the Asia Pacific region during the forecast period. For instance, in September 2019, according to the Indian Brand Equity Foundation (IBEF), India pharmaceutical industry is expected to reach US$ 55 Bn by 2020. Increasing investment by the market players, in order to expand their service and product offerings is expected to boost growth of the cytotoxic drugs contract manufacturing market over the forecast period. For instance, in October 2017, Lonza Group established Lonza Collaborative Innovation Center (CIC) in new Life Science Park in Haifa, Israel. With this, Lonza aims to accelerate leading R&D projects across Lonza's Pharma & Biotech segment, and tap into potentially transformative biological and manufacturing capabilities.

5. North America is expected to dominate cytotoxic drugs contract manufacturing market over the forecast period, owing to adoption of growth strategies such as product launches, investments, facility expansion by the market players in the region to expand their market presence. For instance, in 2016, Cambrex, a leading small molecule API contract manufacturer expanded its facility at Iowa, Charles City-based manufacturing site, adding 1,000- and 4,000 gallon glass-lined reactors in 7,500-square-foot plant. Moreover, market players are focused on collaboration and acquisition strategies to expand their market presence and enhance facility in the region, which is expected to drive growth of the market over the forecast period. For instance, in November 2017, CordenPharma International, a contract provider of both small-molecule APIs and drug products acquired a Hospira Boulder facility from Pfizer Inc., a 54,000-square-foot API manufacturing facility located in Colorado, U.S. to build its capabilities in high-potency manufacturing. According to the expansion strategy, the new facility specializes in development, scale-up, optimization, and production of highly potent and cytotoxic/cytostatic APIs from development to commercialization stage.

6. Key Takeaways of the Cytotoxic Drugs Contract Manufacturing Market: • The global cytotoxic drugs contract manufacturing market is expected to exhibit a CAGR of 1% over the forecast period, owing to increasing adoption of collaboration and acquisition strategies by key players and rising trend of contact manufacturing. Contract development and manufacturing organizations (CDMOs) play a vital role in expediting development of innovative small molecule drug candidates, as these important development activities are often achieved through outsourcing partnerships with CDMOs • Among form, liquid segment held dominant position in the cytotoxic drugs contract manufacturing market in 2018, owing to adoption of expansion strategies by the market players. For instance, in April 2018, STA Pharmaceutical, a subsidiary of WuXi AppTec, signed an investment agreement with the Government of Shanghai, to build a new research & development (R&D) center for APIs and intermediates located next to the company’s existing Jinshan drug-substance manufacturing site.

7. Among product type, intravenous segment held dominant position in the cytotoxic drugs contract manufacturing market in 2018, owing to companies focusing on expansion of their manufacturing facilities for production of sterile injectable and API, in order to increase client base and cater to their demand. For instance, in March 2017, Piramal Pharma Solutions expanded manufacturing capabilities in Lexington, U.S. The new facility includes installation of a new high-speed vial filling line, expansion of the state-of-the art laboratories, and associated utility support. • Companies operating in the global cytotoxic drugs contract manufacturing market include Lonza Group, Piramal Group, Evonik Industries AG, Novasep Holding SAS, Merck KGaA (SAFC Pharma), Baxter Biopharma Solutions, AbbVie Contract Manufacturing, Cambrex Corporation, BSP Pharmaceuticals S.p.A., CordenPharma International, Catalent, Inc., Albany Molecular Research Inc., Evotec, WuXi AppTec Co., Ltd., Pierre Fabre Laboratories, and Dishman Group

8. Request Sample Report Request Customization Download PDF Brochure Talk to Analyst Referance: https://www.coherentmarketinsights.com/market-insight/cytotoxic-drugs-contract-manufacturing-market-3175

9. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. What We Provide:Customized Market Research AnalysisIndustry Analysis ServicesBusiness Consulting ServicesLong Term Engagement ModelCountry Specific Analysis

10. Contact Us Mr. Shah Coherent Market Insights Pvt. LTD.Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S.Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

11. Thank You Kindly Follow CMI Social Media Profiles for the latest Company Updates. Facebook Linkedin Twitter https://www.coherentmarketinsights.com/